Safety of the BNT162b2 mRNA COVID-19 vaccine in oncologic patients undergoing numerous cancer treatment options: A retrospective single-center study

The COVID-19 pandemic, caused by the SARS-CoV2 virus, has infected millions worldwide with cancer patients demonstrating a higher prevalence for severe disease and poorer outcomes. Recently, the BNT162b2 mRNA COVID-19 vaccine was released as the primary means to combat COVID-19. The currently report...

Descripción completa

Detalles Bibliográficos
Autores principales: Kian, Waleed, Zemel, Melanie, Kestenbaum, Emily H., Rouvinov, Keren, Alguayn, Wafeek, Levitas, Dina, Ievko, Anna, Michlin, Regina, Abod, Moataz A., Massalha, Ismaell, Chernomordikov, Elena, Sharb, Adam A., Shalata, Walid, Levison, Esther, Roisman, Laila C., Lavrenkov, Konstantin, Peled, Nir, Nesher, Lior, Yakobson, Alexander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8758044/
https://www.ncbi.nlm.nih.gov/pubmed/35029223
http://dx.doi.org/10.1097/MD.0000000000028561

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8758044/
https://www.ncbi.nlm.nih.gov/pubmed/35029223
http://dx.doi.org/10.1097/MD.0000000000028561

Ejemplares similares